Statement from Stevenage Bioscience Catalyst on GSK’s continued investment in UK life sciences
GSK’s announcement of its continued investment in UK life sciences marks an important moment for the sector. Established in 2012 through a partnership between GSK, the Wellcome Trust and the UK Government, Stevenage Bioscience Catalyst is an independent, not-for-profit organisation dedicated to helping innovative life sciences companies start, grow and succeed.
Memorial for Dr Sally Ann Forsyth OBE DSc
Stevenage Bioscience Catalyst invites colleagues, partners and members of the wider life sciences community to join us in honouring and celebrating the life of our late CEO, Dr Sally Ann Forsyth OBE DSc, at a memorial gathering taking place at 3pm on Wednesday 1 July in the SBC Atrium.
First non-hormonal menopause treatment approved for use in the UK by the MHRA, with early-stage development at Stevenage Bioscience Catalyst
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved elinzanetant (branded as Lynkuet™) for the treatment of moderate to severe hot flushes and night sweats associated with menopause. These symptoms, also known as vasomotor symptoms, affect a significant proportion of women and can have a considerable impact on quality of life.Elinzanetant is the first non-hormonal…
Applications are open for Catalyser 2025, SBC's free accelerator programme
Are you a pre-clinical therapeutics start-up? Stevenage Bioscience Catalyst’s Catalyser programme is an accelerator designed to help businesses attract investors and partners, and maximise overall chances of commercial success.
Samuel Atack appointed as Operations Director at Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst are delighted to announce that Samuel Atack will be stepping into the role of Operations Director at Stevenage Bioscience Catalyst on 1st April 2025 when current Operations Director Dave Mudd retires.
100 guests including local sixth form students attend International Men's Day talks and wellbeing workshop at SBC
We were delighted to welcome over 100 guests to International Men’s Day at Stevenage Bioscience Catalyst.
Stevenage Bioscience Catalyst scoops the Most Successful Science Park (Small) Award at UKSPA40 Anniversary Awards
Congratulations to everyone who took part and for a fantastic and insightful conference from UKSPA, The United Kingdom Science Park Association. Dr Sally Ann Forsyth OBE, CEO of SBC, said: “Stevenage Bioscience Catalyst is truly honoured to win Most Successful Science Park (Small) Award, and for the SBC graduate Autolus Therapeutics to have won Most Successful Company, nominated by SBC as an…
Class of 2023 SBC Catalyser Programme ‘graduate’ with flying colours
Ten startups at the intersection of therapeutics and techbio have celebrated completing Stevenage Bioscience Catalyst’s Catalyser Programme by pitching their ideas and commercialisation strategies to an audience of investors, experts and invited guests.
Lab Hotel at Stevenage Bioscience Catalyst now fully booked
Stevenage Bioscience Catalyst (SBC) has awarded space in its Lab Hotel to start-ups Neobe Therapeutics and Genenet Technology. The Lab Hotel is a unique facility offering free lab and office accommodation for six months.
Inspira Pharmaceuticals joins the Lab Hotel at Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst (SBC) welcomes Inspira Pharmaceuticals to its Lab Hotel, a unique facility offering free lab and office accommodation for six months. The start-ups receive scientific and business support, access to SBC’s networks and introductions to investors to help their business grow and develop.
Free lab and office space available in the Lab Hotel at Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst (SBC) is offering free lab and office accommodation for start-ups – and space is available now. In addition to free accommodation, Lab Hotel occupiers receive scientific and business support, access to SBC’s networks and introductions to investors to help their business grow and develop.
Stevenage Bioscience Catalyst launches accelerator programme for biotech start-ups with opportunity for £10,000 award
Stevenage Bioscience Catalyst (SBC) launches an accelerator programme to give start-ups working on data-enabled drug discovery, genomics and advanced therapies the skills they need to get potential new drugs and therapies to market more quickly.
Report demonstrates Stevenage Bioscience Catalyst’s key role in delivering the economic benefit from leading edge UK life sciences
An independent report has been released today by Stevenage Bioscience Catalyst (SBC) that demonstrates its key role in delivering economic benefit from life sciences research and innovation in the UK.
Biotech start-ups successfully graduate from DATA accelerator programme at Stevenage Bioscience Catalyst
Fifteen start-ups with huge potential have successfully completed the Data-driven Advanced Therapeutics Accelerator (DATA) programme at Stevenage Bioscience Catalyst (SBC), one of Europe’s most important science parks for life sciences.
Dr Sally Ann Forsyth CEO Stevenage Bioscience Catalyst awarded OBE
Dr Sally Ann Forsyth, CEO of Stevenage Bioscience Catalyst (SBC), thanks her colleagues and collaborators after being honoured in the 2021 New Year Honours list. Sally Ann has been awarded an Officer of the Order of the British Empire (OBE) for services to business and science.
Stevenage Bioscience Catalyst opens the Lab Hotel
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce the opening of the Lab Hotel, a lab and office facility for early-stage start-ups in the field of advanced therapeutics and drug discovery. Successful companies have access to the Lab Hotel facilities and support free for six months, with the first…
New report shows 10% of UK’s top female BioBusiness talent is based at Stevenage Bioscience Catalyst
The report released today by BioBeat showcasing the 30 top female leaders in the UK bioscience sector has named three people from organisations based at Stevenage Bioscience Catalyst (SBC), totalling 10% of the list.
Stevenage Bioscience Catalyst opens Spark Building to support cell and gene scale-up
Stevenage Bioscience Catalyst’s new Spark Building opened its doors in January to accommodate the rapid growth of scale-up businesses within Hertfordshire’s world-class cell and gene cluster.
Stevenage named High Potential Opportunity zone for cell and gene therapy
The Department for International Trade (DIT) has classified Stevenage, Hertfordshire, as a High Potential Opportunity (HPO) zone in recognition of its thriving cell and gene therapy cluster of national and international significance. The successful HPO nomination was made by Hertfordshire Local Enterprise Partnership (LEP) and is expected to help attract further overseas investment into the…
SBC occupier Immune Regulation Limited raises £40.6 million Series B equity financing
Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies.
SBC company ReViral raises $44 million in Series C financing
London & Research Triangle Park, N.C. - ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund.
Stevenage Bioscience Catalyst announces Professor Jackie Hunter as new Chair
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Professor Jackie Hunter is to take the role of Chair in September 2020.